Stockwinners Market Radar for September 12, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:49 EDT SEvan Drilling announces comprehensive restructuring plan - Sevan Drilling, a majority owned subsidiary of Seadrill, announced that it has entered into a restructuring agreement with more than 97% of the group's secured bank lenders, approximately 40% of the group's bondholders and a consortium of investors, led by Seadrill's largest shareholder, Hemen Holding Ltd. The agreement delivers $1.06B of new capital in Seadrill comprised of $860M of secured notes and $200M of equity. The group's secured lending banks have agreed to defer maturities of all secured credit facilities, totaling $5.7B, by approximately five years with no amortization payments until 2020 and significant covenant relief. Additionally, assuming unsecured creditors support the plan, the group's $2.3B of unsecured bonds and other unsecured claims will be converted into approximately 15% of the post- restructured equity with participation rights in both the new secured notes and equity. The agreed plan comprehensively addresses the group's liabilities, including funded debt and other obligations. Holders of Sevan common stock will receive no recovery. The agreed restructuring plan was developed over the course of more than a year of detailed discussions, and the plan will ensure that Seadrill can continue to operate its large, modern fleet of drilling units.

18:38 EDT Realty Income raises monthly cash dividend to 21.2c per share from 21.15c - Realty Income Corporation announced that its board of directors has declared an increase in the company's common stock monthly cash dividend to 21.2c per share from 21.15c per share. The dividend is payable on October 13, 2017 to shareholders of record as of October 2, 2017.

18:19 EDT Playa Hotels & Resorts says incurred no significant damage from Irma

17:58 EDT PGT reports no damage in facilities and inventories from Hurricane Irma - PGT Innovations is providing assistance to its employees, customers and communities as they recover from Hurricane Irma. The Company also is providing a preliminary update on its operations following the storm. The Company's facilities were not damaged, and its inventories were not harmed. Its CGI facility in Miami and WinDoor facility in Orlando have power and resumed limited production today. Its PGT facility in Venice had power restored this afternoon, and plans to resume limited production tomorrow. The Company expects to resume full production at its CGI and WinDoor facilities tomorrow, and expects its PGT facility in Venice to be capable of producing at full capacity on Thursday this week.

17:51 EDT Elliott Associates reduces stake in Imperva to 9.5% - Elliott Associates is pleased with the operational progress achieved at Imperva over the last year, including its recent revenue growth of 29% last quarter and its significant operating income improvement. In addition, Elliott Associates is highly supportive of Imperva's new CEO Chris Hylen, who had a strong track record as the CEO of Citrix GetGo. With Imperva's share price appreciating meaningfully from Elliott Associates' cost basis, Elliott Associates has reduced their position in Imperva but remain sizable investors and a top 5 shareholder in Imperva.

17:48 EDT On The Fly: After Hours Movers - HIGHER: Inventure Foods (SNAK), up 26.9% after it agreed to sell its frozen business to Oregon Potato Company for $50M... Senseonics (SENS), up 11.7% after it announced CE Mark approval for its Eversense XL CGM system... Nordstrom (JWN), up 9.4% after CNBC reported that the Nordstrom family is close to a deal to choose Leonard Green to help fund a buyout of the department store chain... Zafgen (ZFGN), up 4.7% after the company initiated a Phase 2 trial for ZGN-1061 in patients with type 2 diabetes... Centene (CNC), up 3.4% after it agreed to acquire substantially all assets of Fidelis Care for $3.75B... Terex (TEX), up 2.1% after Marcato's Mick McGuire said that the company may have "geometric" earnings growth ahead... Micron (MU), up 1.7% after the stock was upgraded to Buy from Neutral at Goldman Sachs. DOWN AFTER EARNINGS: A-Mark Precious Metals (AMRK), down 14.4%... Radiant Logistics (RLGT), down 6.4%. ALSO LOWER: Whiting Petroleum (WLL), down 3.6% after the stock was downgraded to Underweight from Equal Weight at Morgan Stanley... Celldex (CLDX), down 3% after chief medical officer Thomas Davis resigned from the company... AGNC Investment (AGNC), down 3.3% after it filed to sell 24.5M shares of common stock... ON Semiconductor (ON), down 1.4% after the stock was downgraded to Neutral from Buy at Goldman Sachs.

17:38 EDT Marcato's Mick McGuire says input costs hurting Buffalo Wild Wings currently - McGuire says the price of wings are unusually high due to a shortage. McGuire is speaking in a CNBC interview following his presentation at the Delivering Alpha Conference in New York City.

17:32 EDT Boot Barn reports no significant losses from Hurrican Harvey - Boot Barn reported that all of its Houston-area employees are safe. The impact of Hurricane Harvey resulted in conditions that temporarily closed 20 Houston-area stores. All but two of these stores reopened within a week; the two stores that remain closed experienced significant flooding and will be closed until the damage is remediated. While power outages make it difficult to say with certainty that Boot Barn has not experienced any damage to its stores, it does not believe there have been any significant storm-related losses beyond early closures and power outages.

17:30 EDT Boot Barn Holdings completes acquisition of operation of Wood's Boots - Boot Barn Holdings announced that it completed a transaction to acquire the four-store operations of Wood's Boots a family-owned retailer based in Midland and Odessa, Texas. As part of the transaction, Boot Barn purchased the inventory, entered into new leases with the stores' landlord and offered employment to the Wood's Boots team at all four store locations. Boot Barn funded the acquisition from cash on hand.

17:19 EDT NCI Building director acquires 30,000 common shares - In a regulatory filing, NCI Building Systems director George L. Ball disclosed the purchase of 30,000 common shares of the company at a price of $13.40 per share on September 11, 2017.

17:08 EDT Piedmont Office Realty reports no significant damage by recent hurricanes - Piedmont Office Realty Trust announced that its local property teams have reviewed its operations in Texas, Florida and Georgia and is pleased to report that no significant damage was incurred at its buildings. Thankfully, in addition, all personnel in the areas affected by Hurricanes Harvey and Irma are reported to be safe.

17:03 EDT New York Times announces formation of New Products and Ventures group - The New York Times announced key appointments to Product and Design and the formation of a New Products and Ventures group, further defining the new structure it announced in June. These changes streamline and raise the ambitions of the company's digital operations in order to accelerate its rapidly growing digital businesses. Alex Rainert, a veteran product design leader and co-founder of dodgeball, has been named head of Product and Design. In his new role, he will lead the digital product design and product management teams that are responsible for translating The Times's world-class journalism into extraordinary digital products and experiences for its audience. Joining the Product and Design team are Matthew Ericson, who will lead News Experience, and Ben French, who will assume the new role of senior vice president, Reader Experience. Under Mr. Ericson, a longtime editor in the newsroom, News Experience will set the vision for news presentation in core products, and ensure that workflows, tools and processes are aligned with News and Opinion. As head of Reader Experience, Mr. French will work closely with departments across the organization to develop formats and features that will strengthen The Times's relationship with its audience and increase their likelihood to engage and subscribe. Alex MacCallum has been appointed the head of New Products and Ventures, a newly formed team that will include Crosswords and Cooking, and whose charter will be to pursue opportunities for innovation and growth that are brand-congruent yet distinct from The Times's core digital experience. Previously, Ms. MacCallum was an assistant managing editor in charge of video. She also launched and oversaw audience development in The Times newsroom. Reference Link

16:59 EDT MarineMax provided preliminary update on impact of Hurricane Irma - MarineMax provided a preliminary update on the impact of Hurricane Irma. First and foremost, all of the Company's team members and their families are safe. The Company has started efforts to assess the impact of the damage that occurred as a result of Hurricane Irma, which hit two of the Company's largest markets, Florida and the Southeast, U.S. Preliminary indications are that due to the MarineMax team's training, past experiences and proactive efforts to prepare for the storm, buildings and inventory did not incur major damage. Unfortunately, MarineMax Vacations, the Company's charter operation in the British Virgin Islands, sustained significant damage based on initial assessments.

16:54 EDT Exterran estimates $20M loss for production downtime due to Hurricane Irma - Exterran announced the impact of Hurricane Harvey on the Company's operations. No material damage was reported to the Company's two Houston-area manufacturing facilities. Both facilities have returned to full operations. However, both locations were closed for more than a week due to the catastrophic flooding in and around the Houston area. As a result, it is estimated that production downtime will result in up to $20M of revenue and up to $3M in gross margin shifting from the Q3 to future periods. The delayed revenue and gross margin will impact the Company's oil and gas product sales segment. No material changes to other line items are anticipated.

16:45 EDT Inotek Pharmaceuticals trading resumes

16:39 EDT Centene to acquire Fidelis Care assets for $3.75B - Centene Corporation announced that it has signed a definitive agreement under which Fidelis Care will become Centene's health plan in New York State. Under the terms of the agreement, Centene will acquire substantially all of the assets of Fidelis Care for $3.75B, subject to certain adjustments. The addition of Fidelis Care will expand Centene's national leadership in government sponsored healthcare with a leadership position in New York, the country's second largest managed care state by membership. With the addition of New York, Centene will have a leadership position in the country's four largest managed care states by membership - California, Florida, New York and Texas. Upon closing of the transaction, Rev. Patrick J. Frawley will continue to lead Fidelis Care as Chief Executive Officer. Consistent with Centene's local approach, the Company will continue to be headquartered in Queens with operations throughout the state, including, Albany, Buffalo, Rochester and Syracuse. Subject to market conditions, Centene intends to fund the purchase price with $2.3B of new equity, including share consideration, and $1.6B of new long-term debt. The transaction is not contingent upon financing and Centene has secured the full $3.75B in committed bridge financing. Centene expects that its strong balance sheet and the additional cash flow resulting from the acquisition will allow the company to maintain its credit rating and the ability to deleverage on an accelerated basis. The transaction is expected to close in the first quarter of 2018, subject to various closing conditions and receipt of New York regulatory approvals, including approvals under the New York Not-for-Profit Corporation Law.

16:35 EDT Senseonics announces CE Mark approval for Eversense XL CGM system - Senseonics Holdings announced it has received CE Mark approval for the Eversense XL Continuous Glucose Monitoring System. The Eversense XL System includes an extended life implanted glucose sensor lasting up to 180 days, a removable discreet smart transmitter, and a mobile app for display of real-time glucose readings. The Eversense XL System provides the world's longest-lasting sensor, compared to the frequent weekly sensor insertions required by other CGM systems. "We are pleased to announce the CE Mark approval of the Eversense XL System, representing another significant milestone for Senseonics. When we introduced the Eversense System last year, we were providing the longest-wear sensor with up to 90-day wear for people with diabetes. Now with the new Eversense XL System's even longer sensor duration, patients can extend a single sensor wear over 3 seasons - inserting a new sensor in the Fall which will continue through the Winter to be replaced in Spring," said Tim Goodnow, CEO and President of Senseonics. "As we continue to advance our product portfolio with extended long-term sensor capabilities, we are offering added convenience to support patients' continuous glucose management. We are excited to bring this product to market in Europe in the fourth quarter of 2017."

16:32 EDT Vaden Landers reports 12.9% stake in Payment Data Systems

16:25 EDT ComEd says ICC-approved energy efficiency plan to save consumers $4B - The Illinois Commerce Commission yesterday approved ComEd's new four-year Energy Efficiency Plan under the Future Energy Jobs Act. The new plan is set to begin in 2018. It is the first of three energy efficiency plans put in place by FEJA. In total, these plans are expected to generate $4B in customer benefits by 2030, ComEd said. The expanded energy efficiency funding is a key provision of FEJA, which went into effect in June. As part of this first four-year plan, ComEd's investment in energy efficiency programs will be $352M per year, a 40% increase over the previous $250M budget. Significant funding will be provided to grow existing programs for residential and business customers, such as product rebates, energy assessments, weatherization offerings, and retrofitting initiatives. There also will be $42M per year in funding set aside for low-income energy efficiency programs and $50M over the life of the plan for research and development of new and innovative products and services.

16:24 EDT Enable Midstream to acquire Align Midstream - Enable Midstream announced it has entered into a definitive agreement to acquire Align Midstream, which owns natural gas gathering and processing assets in the Cotton Valley and Haynesville plays of the Ark-La-Tex Basin, for approximately $300M, subject to certain customary adjustments. This strategic acquisition extends Enable's footprint in areas with increasing producer activity and is expected to be accretive to Enable's 2018 distributable cash flow per unit. Align operates approximately 190 miles of natural gas gathering pipelines across Rusk, Panola and Shelby counties in Texas and DeSoto Parish in Louisiana and a cryogenic natural gas processing plant in Panola, Texas, with a capacity of 100M cubic feet per day. Align's assets are underpinned with long-term, fee-based contracts, including approximately 100,000 gross acres of dedication from producer customers.

16:18 EDT Rayonier Advanced Materials restarts operations in FL, GA after Irma - Rayonier Advanced Materials announced that it is beginning to restart core systems at its Fernandina Beach, Fla. and Jesup, Ga. facilities after Hurricane Irma passed through the area. The company expects operations to be running at full production capacity by the weekend. The pre-emptive shutdown was managed safely with no injuries and limited physical damage to the facilities. The company is coordinating with suppliers and logistic partners to help ensure a safe and efficient restart of operations with minimal customer disruption.

16:17 EDT American Airlines reports August traffic up 3.7% - American Airlines Group reported August and year-to-date 2017 traffic results.American Airlines Group's total revenue passenger miles, RPMs, were a record 21.2B, up 3.7% versus August 2016. Total capacity was 25.5B available seat miles, ASMs, up 3.2% versus August 2016. Total passenger load factor was 83.3%, up 0.4% points versus August 2016. As of the end of August, the company's estimate for its third quarter total revenue per available seat mile, TRASM, was in line with prior guidance of up 0.55t to up 2.5% year-over-year. However, Hurricane Irma caused closures at 40 airports in Florida and the Caribbean, including the company's hub at Miami International Airport, and resulted in more than 5,000 flight cancellations. Based on preliminary estimates of the financial impact of the storm, the company now expects its third quarter 2017 TRASM to be approximately flat to up one percent year-over-year. Including the impact of higher fuel costs for the quarter, the company now expects its third quarter 2017 pre-tax margin excluding special items1 to be between 8.5% and 10.5% vs. the company's previous guidance of between 10% and 12%. The company continues to believe that fourth quarter TRASM growth will exceed third quarter growth.

16:17 EDT Inotek Pharmaceuticals announces merger pact with Rocket Pharmaceuticals - Inotek Pharmaceuticals announced that they have entered into a definitive merger agreement with Rocket Pharmaceuticals Ltd., a US-based gene therapy company. Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City. The combined company will focus on developing and advancing its pipeline of gene therapies based on lentiviral virus and adeno-associated virus gene therapy platforms, with a focus on treating devastating rare diseases. "We have conducted an exhaustive strategic process focused on proactively identifying assets that have clear biological plausibility and a high unmet need. As a result of this process, I'm delighted to announce a merger with Rocket as the best scenario for value creation for our stockholders," said David P. Southwell, President and Chief Executive Officer of Inotek. Under the terms of the merger agreement, shareholders of Rocket will receive shares of newly issued Inotek common shares in a private placement. Rocket shareholders are expected to own approximately 81% of the combined Company and current Inotek shareholders will own approximately 19% of the combined Company. The percentage of the combined Company that Rocket's shareholders will own as of the close of the transaction is subject to adjustment based on the amount of Inotek's net cash at the closing date. The merger agreement contains further details with respect to this adjustment and the transaction. The transaction has been unanimously approved by the Board of Directors of both companies. The merger is expected to close in the first quarter of 2018, subject to customary closing conditions, including the approval by stockholders of Inotek. Gaurav Shah, MD, will serve as Chief Executive Officer of the combined company.

16:16 EDT Leidos awarded $49M contract by USACE - Leidos was awarded a prime contract by the U.S. Army Corps of Engineers, or USACE, St. Louis District, to provide hazardous, toxic and radioactive waste, or HTRW, investigations and environmental remediation. The single-award, indefinite delivery/indefinite quantity, cost-plus fixed-fee contract has a one-year base, with an ultimate completion date of February 2023 if all options are exercised. Total contract value is approximately $49M. Work will be performed primarily in St. Louis, Mo., and Burlington, Iowa.

16:13 EDT Matrix Service awarded two capital projects - Matrix Service Company announced that its subsidiary, Matrix NAC, has been awarded two separate blast furnace repair projects in the iron and steel industry, both of which will enhance the infrastructure, stability, efficiency and material handling of the associated facilities.

16:11 EDT Inotek Pharmaceuticals trading halted, news pending

16:10 EDT China Pharma receives not in compliance letter form NYSE American - China Pharma Holdings announced receipt of notification from the NYSE AMERICAN that the Company is not in compliance with certain NYSE American continued listing standards or the Listing Standards. The Deficiency Letter indicated that the Company's securities have been selling for a low price per share for a substantial period of time and, most recently, the average price of the Company's common stock had been below 20c on a 30-day average as of September 5. The Company's common stock will continue to be listed on the NYSE American while it attempts to regain compliance with the Listing Standards, subject to the Company's compliance with other continued listing requirements.

16:09 EDT Alimera Sciences announces Iluvien available in Ireland - Alimera Sciences announced that Iluvien, its sustained release intravitreal implant for the treatment of diabetic macular edema, or DME, is now available in Ireland through VHI Healthcare Group, the leading Irish healthcare provider. "Diabetes remains the most serious cause of severe vision loss in people of working age in Ireland, and diabetic macular edema is the cause in around 10% of those cases," said Marie Hickey Dwyers, former president of the Irish College of Ophthalmologists. "The approval of Iluvien in Ireland is exciting news for all those patients who are no longer responding to their first-line DME treatment. The Iluvien implant could mean the difference between a patient having increasingly deteriorating sight, and being able to drive again. I look forward to having Iluvien as an option for my patients."

16:08 EDT Allergan launches new Brilliant Distinctions patient loyalty program - Allergan announced that the company is launching the next generation of its groundbreaking U.S.-based Brilliant Distinctions program. The new offering incorporates the latest in digital innovation to enhance the consumer experience and drive increased member engagement. In addition, Brilliant Distinctions is also expanding to include the latest addition to the Allergan aesthetic portfolio, CoolScuplting, in the body treatments category. CoolSculpting non-invasively freezes fat in indicated body areas to help eliminate unwanted visible fat bulges. In the facial aesthetics category, the program provides savings to patients for loyalty and frequency of treatments and products, such as BOTOX Cosmetic, the JUVEDERM Collection of Fillers, the SkinMedica cosmetic skincare line, and Latisse.

16:06 EDT DDR Corp. reports minimal damage in Southeast from Hurricane Irma - DDR Corporation announced that upon initial inspection, the company's shopping centers in Florida, South Carolina, and Georgia have sustained only minor damage as a result of Hurricane Irma. Beyond power outages, the scope of damage has been limited to tree and debris removal and damage to landscaping, and there appears to be no major structural damage to report.

16:05 EDT Legg Mason reports August preliminary AUM $752.4B - Legg Mason reported preliminary assets under management of approximately $752.4B as of August 31. This month's AUM included long-term outflows of $1.5B, consisting of net outflows in equity of $800M, fixed income of $500M and alternative of $200M. Fixed income outflows included a previously disclosed $2.6 billion low-fee redemption. Alternative AUM reflects realizations of $100M. Liquidity outflows were $1.6B and this month's AUM included a negative foreign exchange impact of $400M.

16:04 EDT Pacific Drilling trading halted, news pending

16:03 EDT Celldex Chief Medical Officer Thomas Davis resigns - Celldex Therapeutics announced the resignation of Thomas Davis, M.D., executive VP and Chief Medical Officer of Celldex, effective September 29.

15:58 EDT Brown Brothers Harriman & Co. reports 5.04% passive stake in FleetCor

15:44 EDT Dimon says successor CEO is inside JPMorgan

15:34 EDT Disney says 'Star Wars: Episode IX' scheduled for release December 20, 2019 - J.J. Abrams is returning to complete the Star Wars sequel trilogy as writer and director of "Star Wars: Episode IX," Disney announced. "Star Wars: Episode IX" is scheduled for release on December 20, 2019, the company noted. Reference Link

15:31 EDT NY AG: Customers won't have to waive legal rights for Equifax protection offer - New York State Attorney General Eric Schneiderman tweeted: "After conversations w/ my office, #Equifax has now made it explicitly clear-no one will waive their right to join a class action." Reference Link

15:11 EDT Continental Resources drops after mentioned by Chanos as short - Kynikos Associates founder James Chanos mentioned he is short Continental Resources according to media coverage of CNBC's Delivering Alpha event.

15:01 EDT New Jersey Resources raises quarterly dividend 6.9% to 27.25c per share - The new quarterly rate will be effective with the dividend payable October 2 to shareowners of record on September 22.

14:57 EDT Apple iPhone 8, 8 Plus available September 22, starting at $699 - Apple announced the iPhone 8 and iPhone 8 Plus, which feature a new glass and aluminum design in three colors "made out of the most durable glass ever in a smartphone," Retina HD displays and A11 Bionic chip. The phones, "designed for the ultimate augmented reality experience," have single and dual cameras featuring Portrait Lighting on iPhone 8 Plus along with wireless charging. Both devices will be available for pre-order beginning Friday, September 15 in more than 25 countries and territories, and in stores beginning Friday, September 22. iPhone 8 and iPhone 8 Plus will be available in space gray, silver and an all-new gold finish in increased 64GB and 256GB capacity models starting at $699.

14:52 EDT Apple iPhone X available November 3, starting at $999

14:50 EDT Apple says iPhone X will start at $999, will ship on November 3

14:47 EDT Energous halted again as shares jump off lows during Apple iPhone event

14:43 EDT Apple says iPhone X has two more hours of battery life than iPhone 7

14:40 EDT Apple shares reverse, turn negative as iPhone launch event continues - Apple shares, which rose to as high as $163.96 earlier in the session, are now down about 0.7% to $160.37 as company executives continues to demonstrate features of the new iPhone X.

14:31 EDT Apple says iPhone X has Face ID, works with Apple Pay, third-party apps

14:30 EDT Bank of America: 'No reason' to adjust mid-single digit business loan forecast

14:23 EDT Apple says iPhone X has surface to surface display, no 'Home' button

14:22 EDT Bank of America: 'No one place' to cut expenses across bank - Says has been adding sales professionals while reducing overall headcount. Says grew revenue 7% in 1H17. Says "no one place" to cut expenses across the bank.

14:19 EDT Energous drops, halted for volatility as Apple details wireless charging plans - Energous is down $1.59, or 12.95%, to 10.65 as Apple holds its iPhone launch event.

14:17 EDT ConocoPhillips backs FY17 production view 1,340-1,370 MBOED

14:17 EDT ConocoPhillips backs Q3 production view 1,170-1,210 MBOED - Says Q3 guidance excludes Libya and reflects expected impacts from the San Juan, Barnett and Panhandle dispositions.

14:17 EDT Apple says iPhone 8 will ship on September 22

14:15 EDT Lumentum, Finisar move to highs as Apple discusses AR features of iPhone - Piper Jaffray analyst Troy Jensen has previously said he sees the 3D sensing market is a "significant earnings enhancement opportunity" for Lumentum (LITE), while Finisar (FNSR) recently blamed a manufacturing process tweak for pushing out 3D sensor sales by a quarter.

14:12 EDT Bank of America: Earnings have 'steadily' improved since 2014 - Says has flexibility to continue to deliver to customers "when times are tough." Says earnings have "steadily" improved since 2014. Says net charge-offs have declined. Says decline reflects change in underwriting standard since 2008 financial crisis. Says committed to "responsible" growth. Comments taken from Barclays Global Financial Services Conference.

14:00 EDT Apple says iPhone 8 has A11 Bionic chip

13:58 EDT Apple TV 4K available September 22, starting at $179 - Apple introduced the new Apple TV 4K with support for both 4K and High Dynamic Range. iTunes users will get automatic upgrades of HD titles in their existing iTunes library to 4K HDR versions when they become available, the company announced. Apple TV 4K will also offer 4K HDR content from video services, including Netflix (NFLX) and Amazon Prime Video (AMZN), coming soon. Apple TV 4K starts at $179 for 32GB or $199 for 64GB, joining Apple TV 4th generation 32GB at $149. Customers will be able to order both Apple TV 4K models beginning Friday, September 15, with availability beginning Friday, September 22.

13:54 EDT Dimon: 'Shame on us for not having provided Venmo-type payment services earlier

13:48 EDT Apple says Apple TV bringing live sports, live news to TV app

13:44 EDT BRT Realty Trust trading resumes

13:42 EDT Dimon says may look to raise dividend vs. buybacks

13:39 EDT BRT Apartments Corp. initiates quarterly dividend of 18c per share - BRT Apartments Corp. announced that its board of directors initiated and declared a quarterly dividend on the company's common stock of 18c per share. The dividend is payable October 4, 2017 to stockholders of record on September 25, 2017.

13:36 EDT JPMorgan's Dimon says 'quite bullish' about IB business

13:33 EDT Dimon: Chase Sapphire Reserve premium card performing about as expected

13:32 EDT Apple says Apple Watch Series 3 available 'next month'

13:20 EDT JPMorgan's Dimon sees trading revenue down about 20% in Q3

13:20 EDT JPMorgan's Dimon says may no longer give guidance on trading going forward - Says 2% economic growth of last few years just half of a normal recovery. Says regulatory environment has not changed a lot. Says Treasury has laid out "very good map" of issues that should be looked at. Believes regulations will ease over time, helping U.S. economy. Believe GDP "moving a little faster than the numbers show." Says "we're not predicting bad things, but we're prepared." As QE reverses, says "hold onto your hats." Says considering not giving guidance on trading going forward.

13:12 EDT JPMorgan CEO Dimon: 2% growth just half of a normal recovery

13:11 EDT CDI Corp. trading resumes

13:04 EDT BlackBerry updates Enterprise Mobility Suite to support Apple's iOS 11 - BlackBerry (BBRY) announced that the entire BlackBerry Enterprise Mobility Suite has been updated to fully support Apple's (AAPL) newly launched iOS 11 mobile operating system. For IT departments, BlackBerry has made it easy to support iOS 11's end user enhancements and enterprise capabilities by ensuring that all of the essential BlackBerry apps their companies rely on to secure the work of their iOS users are updated in the App Store and available for immediate download now. For enterprise environments that allow it, end-users will note that their BlackBerry Enterprise Mobility apps have already been auto-updated.

13:02 EDT Chanos says McDonald's taking share in restaurant space - Jim Chanos of Kynikos Associates said on CNBC that he's been short the restaurant space over the past year. McDonald's is taking market share in the burger space, Chanos said. Competitors of the fast food chain include Wendy's (WEN), Sonic (SONC), Habit Restaurants (HABT) and Jack in the Box (JACK).

12:58 EDT Cooperman sees United Continental shares going to $100 - Leon Cooperman said at CNBC's Delivering Alpha conference today that he sees shares of United Continental going to $100 over the next 12-18 months. United in midday trading is up 72c to $61.18.

12:50 EDT Chanos says long all but one of the FANG stocks - Jim Chanos of Kynikos Associates is speaking on CNBC.

12:49 EDT Jim Chanos is short pharmacy benefit manager industry - Jim Chanos of Kynikos Associates, while speaking on CNBC, said he's short the pharmacy benefit manager industry, and more specifically, "bad actors." Names in the sector include Express Scripts (ESRX), UnitedHealth (UNH) and CVS Health (CVS).

12:46 EDT Chanos says 'no evidence' Mallinckrodt's Acthar works

12:45 EDT Chanos says no evidence that Mallinckrodt's Acthar works - Jim Chanos of Kynikos Associates is speaking on CNBC.

12:31 EDT Nvidia drops after NTSB urges restrictions on car automation - Shares of semiconductor maker Nvidia (NVDA) are lower after Bloomberg and other news outlets reported on the NTSB comments following the Safety Board meeting on Tuesday, September 12, to determine the probable cause of the fatal, May 7, 2016, crash of a Tesla (TSLA) car near Williston, Florida. According to the reports, on Tuesday, the NTSB urged manufacturers and government regulators to restrict car automation. Shares of Nvidia are down 1% to $167.40 while Tesla is up fractionally to $365.60 in early afternoon trading. Nvidia manufactures DRIVE PX, an open AI car computing platform that enables automakers and tier 1 suppliers to accelerate production of automated and autonomous vehicles.

12:18 EDT Chanos says Alibaba revenue driven by affiliates

12:15 EDT Chanos says just as bearish on Tesla as he's been - Kynikos Associates founder James Chanos is speaking on CNBC.

12:03 EDT Netflix CFO says company not getting into live sports

12:01 EDT Netflix CFO says 'very close' to being cash flow positive

11:50 EDT Team Inc confirms receipt of letter from Engine Capital - Team, Inc. confirmed that it has received a letter from Engine Capital. Team regularly engages with its shareholders in the ordinary course of its business. The company appreciates constructive input from its shareholders and takes their views seriously. The Board of Directors is in the process of evaluating the important issues raised in the Engine Capital letter and intends to respond as soon as it determines the appropriate courses of action.

11:47 EDT Euroseas acquires two container feeder vessels - Euroseas announced that it signed a memorandum of agreement to purchase the M/V EM Athens and EM Oinousses, both feeder size containership vessels of 2,506 teu built in 2000. The company also announced that it acquired the option to purchase from Euromar two additional container vessels, the M/V EM Corfu, a feeder size containership vessel of 2,556 teu built in 2001, and the M/V Akinada Bridge, a post-panamax size container vessel of 5,600 teu built in 2001 until September 30, 2017. The vessels are to be acquired for a combined amount of about $25M from Euromar, a wholly-owned subsidiary of the company that previously was partially owned by the company, as discussed below. The company plans to finance the acquisitions with a combination of debt and equity. The vessels are expected to be delivered to the company in the fourth quarter of 2017. Furthermore, the company announced that it acquired the 85.714% interest in Euromar it did not already own for nominal cost. As a result of the acquisition, Euromar, which was a joint venture among the company and two private equity firms, became a wholly-owned subsidiary of the company. The company has provided no guarantees to Euromar's lenders, and none of the lenders has any recourse against the company. Euromar, in addition to the four vessels sold or expected to be sold as described above, owns five other vessels, four of which are feeder containerships and one Intermediate size containership.

11:41 EDT Netflix says 2019 break with Disney 'quite anticipated' - Says 2019 content break with Disney was "quite anticipated a little bit on both sides." Says would prefer to own great shows than license content.

11:31 EDT Caterpillar sees Construction Industries up approximately 15% in 2017 - Caterpillar sees Construction Industries, or CI, up approximately 15% in 2017. Sees road construction as biggest driver in CI mix. Comments are from Construction Industries Group President Bob De Lange.

11:19 EDT Consolidated Water provides update on impact of Hurricane Irma on operations - Consolidated Water provided an update regarding the impact of Hurricane Irma on its operations. President and CEO Rick McTaggart stated: "As Hurricane Irma made landfall in the Caribbean and Florida, our thoughts have been with the people and communities affected, and the wellbeing of our employees has been our priority. We are grateful that our team is safe. Due to loss of power, our desalination plants in the British Virgin Islands remain closed following the severe damage from winds and flooding that the Islands of Tortola and Jost Van Dyke endured from Hurricane Irma. These plants represent 800,000 gallons of daily production, equivalent to 3% of our total water capacity. We are currently unable to estimate how long it will take for power to be restored to Tortola and Jost van Dyke because of the extensive damage to the country's infrastructure, and are also working directly with Government officials to expedite the importation of emergency power equipment. From what we know today, the physical structures of our plants there appear to be intact but without electrical power we are unable to determine whether they are operable. Neither of our three water desalination plants located in the Bahamas sustained damage from the Hurricane. Our Aerex subsidiary in Ft. Pierce, Florida is currently without power but we expect power to be restored within a matter of days, after which we can recommence full manufacturing activities at Aerex. We will continue to closely monitor the situation and report on any material developments."

11:14 EDT Caterpillar will emphasize services especially aftermarket - Sees each division creating enough cash flow to reinvest in the business.

11:12 EDT Caterpillar sees CapEx less than depreciation and amortization for 'some time'

11:06 EDT Blackstone CEO Schwarzman says still talks to President Trump - Blackstone CEO Steve Schwarzman said at CNBC's Delivering Alpha conference said he continues to talk to President Trump following the disbanding of the CEO councils.

10:58 EDT Caterpillar says 'mining industry improving' - Comments taken from slides presentation for company's investor day.

10:53 EDT Comcast says 'pleased' with early results of Xfinity Mobile - Says working on segmented ways to gain customers for X1 video product. Sees internet business growth well into the future and accretive to margins. Says Comcast Business on path to grow revenue at double-digit rate and accretive to margins. Says Xfinity Mobile off to great start. Says may be most profitable year in Universal history. Says focused on delivering consistent, profitable growth. Comments taken from Goldman Sachs Communacopia Conference.

10:43 EDT State Street sees Q3 markets revenue seasonally down sequentially, flattish y/y - Comments made by CFO Eric Aboaf at the Barclays Global Financial Services Conference.

10:32 EDT Preferred Aparment reports no 'significant' damage after Hurricane Irma - Preferred Apartment Communities announced that in the wake of Hurricane Irma, it is pleased to report that none of its assets owned in Florida and Georgia have suffered significant property damage or flooding. The company said, "At this time, we do not expect the storm's damage to have a meaningful impact on our results or performance. The condition of our investments and the timely delivery of information is a tremendous credit to our on-site staff and management personnel who have worked so tirelessly in the last week to prepare us for Irma's arrival. The youth of our portfolio and the quality of construction of our assets has certainly been a key factor in weathering this storm. In addition to the work being done as a result of Irma, we are working quickly to repair the damage done by Hurricane Harvey to our asset, Stone Creek, in Port Arthur, outside of Houston. Stone Creek had flooding in the first floor units and clubhouse from Hurricane Harvey two weeks ago. Our management team had remediation teams in the units at Stone Creek within 48 hours to begin the process of getting our affected units back on line. Stone Creek was a participant in the National Flood Insurance Program and we believe all of the damage done by the storm will be covered by our insurance policies."

10:30 EDT IAM, USW terminate partnership agreement with Harley-Davidson - The International Association of Machinists and Aerospace Workers and the United Steelworkers announced that they are withdrawing from their partnership agreement with Harley-Davidson, citing "a deep and strong concern with the way Harley management is dealing with seasonal production." The unions added in their press release that they "no longer sees a sufficient partnership in the decision-making process that existed in prior years."

10:17 EDT Ultimate Software says presentation at Deutsche Bank conference canceled - Ultimate Software announced that Mitchell Dauerman, Ultimate's CFO, EVP and treasurer, will no longer present at the Deutsche Bank Technology Conference in Las Vegas, Nevada. Dauerman originally had been scheduled to present on Tuesday, September 12, at 4:10 p.m. Pacific time. The cancelation is due to travel restrictions throughout Florida caused by Hurricane Irma. Business operations at Ultimate Software have not been impacted.

10:12 EDT Dalio says Gary Cohn leaving Trump administration would be 'terrible' - Ray Dalio of Bridgewater Associates is at CNBC's Delivering Alpha conference.

10:02 EDT McDonald's weakness attributed to cautious M Science mention - The move lower in shares of McDonald's is being attributed to a research report from M Science, which is said to be cautious on the company's quarter following channel checks. Shares of McDonald's are down 2% to $157.70 in early trading.

09:57 EDT Condor Hospitality Trust provides Hurricane Irma update - Condor Hospitality Trust announced that its Florida hotels, the Home2 Suites Tallahassee, the Hampton Inn & Suites Lake Mary, and the Courtyard Jacksonville, are all operational and have not sustained any significant damage from Hurricane Irma. The company will provide additional information or updates in the event of a material change in this situation. "All of our Texas and Florida hotels are in good shape and operational following Hurricanes Harvey and Irma," stated Jeff Dougan, Condor's COO. "Any physical damage is minor and we will pass along any material updates as we receive them," continued Dougan.

09:33 EDT Samsung, Charter to collaborate on 5G trials in U.S. - Samsung Electronics America (SSNLF) and Charter Communications (CHTR) announced that they are collaborating on 5G and 4G LTE wireless networks lab and field trials at various locations in the U.S. The trials, which began this summer, will run through the end of the year. The 5G trial is evaluating fixed use cases using Samsung's pre-commercial 28 GHz system and devices. The 4G trials are performed at 3.5 GHz, utilizing Samsung's combined 4G LTE small cell technology in an outdoor environment to evaluate mobile use cases.

09:29 EDT On The Fly: Pre-market Movers - HIGHER: Apple (AAPL), up just under 1% ahead of the tech giant's launch event... Alexion Pharmaceuticals (ALXN), up 2.1% after announcing restructuring plan... DowDuPont (DWDP), up 1.3% after announcing results of comprehensive portfolio review and realigning into three intended companies. LOWER: Brookfield Infrastructure (BIP), down 5.6% after its 16.6M share Spot Secondary priced at $42.10... Nucor (NUE), down 1% after being downgraded to Equal Weight from Overweight at Morgan Stanley.

09:27 EDT OSI Systems receives $9M order for cargo and vehicle inspection systems - OSI Systems announced that its Security division received an order totaling approximately $9M to provide multiple platforms of cargo and vehicle inspection systems, including civil works and installation support.

09:26 EDT Aurigene to initiate Phase 2 trial of CA-170 in India - Aurigene Discovery Technologies, a wholly owned subsidiary of Dr. Reddy's Laboratories (RDY), announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India. This was announced following the presentation of preliminary data from the initial 34 patients with cancer treated in the dose escalation stage of the Phase 1 trial of CA-170 at the European Society for Medical Oncology 2017 Congress by Aurigene's collaborator and licensee of CA-170, Curis, (CRIS). The trial has been conducted in the U.S., South Korea and Spain. The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA. Data presented at the ESMO 2017 conference represent the initial 34 patients treated to date in the dose escalation Phase 1 trial. 30 patients were naive to prior immunotherapy treatment, while four patients had experienced prior treatment with approved anti-checkpoint antibodies. No dose limiting toxicities were observed at doses ranging from 50 mg to 800 mg once daily dosing examined thus far. CA-170 demonstrated good oral bioavailability and plasma drug levels were shown to increase in a near-linear manner with increasing doses. Evidence of immune modulation, including an increase in activated CD8+ T cells, was observed in patient blood and tumor biopsy samples examined following treatment. Of the 21 patients evaluable for disease assessment, 13 patients experienced disease stabilization. Four immunotherapy treatment-naive patients treated with CA-170 experienced shrinkage of their tumors. Six patients remained on drug treatment beyond three months, including all four patients with tumor shrinkages. In addition, seven of the 34 patients remain on study and are continuing with treatment.

09:16 EDT Comerica says $2.5B of loans could be impacted by Hurricane Harvey - Says 8% of total CMA loans managed in Houston; 5% of total CMA loans with operations in Houston area. Says three banking centers in Houston market remain closed as of September 11. Sees less than $1M in expected costs to rebuild and repair. Says $2.5B of loans could be impacted by Hurricane Harvey. Says any losses will be manageable or covered by insurance. Says "too soon" to assess impact of Hurricane Irma. Says had expected strong momentum from Q2 to continue in Q3, but says customers increasingly cautious as progress in Washington "stymied," global tensions have risen. Says deposits continued to decline through middle of July, then began to rebound, in line with normal seasonal pattern. Comments made by Chairman and CEO Ralph Babb, Jr. at the Barclays Global Financial Services Conference. Comerica is up about 0.8% in premarket trading.

09:15 EDT Health Insurance Innovations addresses 'misleading information' - Health Insurance Innovations held a conference call Monday to give a management update. As a follow-up to that call, the company provided the following statement to address certain misleading information in the marketplace, including information in a third-party investor report issued Monday: The Indiana Multi-State examination is an open matter, where the lead regulators have not yet provided any written findings, or a framework for resolution. A third-party report published yesterday referred to a potential estimated combined fine amount of $100M, which the author based on unstated or inapplicable data points. This amount does not correspond to any estimates, analyses, or communications undertaken or made by the company, and the company does not believe that this number has any basis in fact. The company has cooperated fully and in a transparent manner in all matters. HIIQ's regulatory matters are publicly disclosed in SEC filings, after working diligently with counsel to provide appropriate detail related to any active investigations. Closed matters, such as those in Arkansas and Ohio, neither of which concluded with regulatory action from the respective states. As previously disclosed by the company, in June 2017 the Florida Office of Insurance Regulation, or OIR, denied the Company's application for licensure as a TPA based on the OIR's determination that the company had not provided all information required to process the application. In June 2017, the company appealed the denial with the Florida Division of Administrative Hearings in order to preserve its rights. A final hearing on the appeal was originally scheduled for October 17-20, 2017, but the proceeding is on hold, and the company is currently engaged in a dialogue with the OIR on a potential resolution that would enable the company to withdraw the appeal and either re-submit the application or engage in discussions regarding whether the OIR will require the company to hold a TPA license at all. In a report issued yesterday by a third party, the author of the report mischaracterized certain disclosure questions that arose during the application process regarding prior legal proceedings involving Michael Hershberger, the company's CFO. In connection with the licensing application process, the company received comments from OIR about the need to disclose certain prior legal proceedings involving Mr. Hershberger. Those legal proceedings involved Mr. Hershberger's prior business as a real estate developer in the Dane County, Wisconsin area. One case involved a monetary claim that was quickly settled, and another case was one in which Mr. Hershberger was mistakenly named as a party. Mr. Hershberger has provided all requested information, and no information is outstanding in regard to these matters. These matters are not significant, and there are no "undisclosed legal actions against HIIQ insiders". Similar misleading statements were made in the third-party report regarding legal proceedings involving Michael Kosloske, as those proceedings involved a car accident and an employment agreement dispute with a prior employer, both of which Mr. Kosloske initially believed were not responsive to the requirements of the TPA application, but we subsequently provided. In addition to the above, a third party yesterday took out of context a statement made by counsel to the company in a letter to OIR regarding a "domino effect". The company's counsel was making a reference to the fact that an application denial would likely be a disclosure item on all future licensing in other states, which would add significant work to future licensing efforts in those states. "Since its inception, the company has operated in the State of Florida under an Agency License issued by the Florida Department of Financial Services that allows the company to sell insurance products in the state. Many states, including Florida, have statutes that require the licensure of TPAs, and the statutes and applicable regulations vary from state-to-state with respect to the nature of the business activities that may require licensure. Because the company's business model does not fall into the category of business activities ordinarily contemplated by state TPA statutes, the need for the company to become licensed as a TPA in a particular state is not always clear and generally involves an analysis and dialogue with applicable state regulators. As of today, the company applied for and obtained TPA licenses in approximately 34 states, and applications in 8 states are pending, and in other states the company confirmed that licensure is not required. The company has operated in the State of Florida since its inception, and based on discussions with the OIR, the company determined that its business activities likely require licensure as a TPA even though the company is not a traditional TPA. Although the company has pursued the licensure process described above, the company believes that further contemplated dialogue with OIR could result in a conclusion that TPA licensure is not necessary, and otherwise the company intends to seek such licensure and has since provided all information requested by the OIR. The OIR has not to date informed the company that it intends to request that the company modify its business activities in Florida, and the company is in regular communication with the OIR on other compliance matters."

09:12 EDT Array BioPharma announces FDA accepted NDAs for COMBO450 - Array BioPharma announced that the FDA has accepted for review its New Drug Applications, or NDAs, to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily, or COMBO450, for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA set a target action date under the Prescription Drug User Fee Act , or PDUFA, of June 30, 2018 for both applications. In addition, the FDA informed Array that based on their preliminary review of the applications they have not identified any potential review issues, and that they are not currently planning to hold an advisory committee meeting to discuss these NDAs.

09:06 EDT Raytheon awarded $119M contract by U.S. Navy - The U.S. Navy awarded Raytheon a $119M contract to begin integrating a new multi-mode seeker into the Tomahawk Block IV cruise missile. The enhancement will enable the weapon to engage moving maritime targets. The Navy is conducting the new seeker development as a Rapid Deployment Capability program to meet urgent fleet requirements for defeating emerging maritime threats worldwide. Raytheon is expected to deliver this new capability by 2022.

09:04 EDT L3 Technologies acquires Adaptive Methods - L3 Technologies announced that it has acquired Adaptive Methods. The acquisition was completed on September 8, and the terms were not disclosed. The business will be renamed L3 Adaptive Methods and will be integrated into L3's Sensor Systems business segment. Based in Centreville, Virginia, Adaptive Methods is a systems engineering company that delivers Undersea Warfare and Anti-Submarine Warfare capabilities for U.S. military customers. It is also developing autonomy and sensor payload solutions for use by Unmanned Undersea Vehicles. Additionally, the company provides tactical buoy systems for manned and unmanned platforms, as well as ASW sonar processing systems and displays and command and control/theatre ASW systems.

09:03 EDT Comcast, Google announce integrated YouTube app on Xfinity X1 - Comcast (CMCSA) and Google (GOOG, GOOGL) announced the nationwide launch of YouTube on Xfinity X1, giving viewers quick, easy access to YouTube's vast online video collection alongside the live, on demand, DVR and other web programming that is already included with their Xfinity TV subscription. YouTube content will be accessible via the X1 voice remote and YouTube videos will be featured throughout Xfinity on Demand. YouTube's online videos will be featured throughout the Xfinity On Demand menu and available in the YouTube app, providing easy access to trending videos and complementing existing movie, show, music, news, and celebrity content screens on X1 and supplementing thematic destinations. Current X1 and YouTube signed-in customers can readily access their personalized settings and subscriptions when accessing YouTube on X1. In addition to finding YouTube content with the X1 voice remote and within Xfinity On Demand, customers can just launch the YouTube app located in the Apps and Networks sections of X1.

09:01 EDT American Vanguard acquires Grupo Agricenter - American Vanguard Corporation announced that its wholly owned subsidiary AMVAC Netherlands BV, will acquire Grupo Agricenter to reinforce its commercial, technical and development structure in the Latin-American region. Both parties have announced October 2, 2017 as the official closing date for this transaction. The terms of the acquisition were not disclosed.

08:58 EDT Mnuchin says CEO councils disbanding was a 'mistake' - Treasury Secretary Steve Mnuchin is speaking on CNBC.

08:54 EDT Mnuchin says 'actively involved' in Equifax breach - Treasury Secretary Steve Mnuchin, while speaking on CNBC, said the recent Equifax is "quite unfortunate" and that he's "actively involved" in it.

08:53 EDT BB&T sees total loans slightly down in Q3 vs. Q2 - Sees Q3 NCOs 35-45bps, NPAs expected to be in a similar range vs. Q2. Sees Q3 GAAP net interest margin stable vs. Q2, core margin stable vs. Q2. Sees Q3 net interest income stable vs. Q2. Sees Q3 noninterest income slightly down vs. last year. Sees expenses flat to up 2% vs. last year. Comments from slides that will be presented at the Barclays Global Financial Services Conference.

08:48 EDT NeuroDerm holders approve proposed acquisition by Mitsubishi Tanabe Pharma - NeuroDerm announced that at NeuroDerm's extraordinary general meeting of shareholders held today, NeuroDerm shareholders voted to approve the previously announced acquisition by Mitsubishi Tanabe Pharma and all transactions and arrangements contemplated under the related merger agreement, including the merger of MT Porto Ltd., a wholly-owned subsidiary of MTPC with and into NeuroDerm. At the meeting, 19,093,606 ordinary shares, or approximately 100 percent of votes cast at the meeting, voted in favor of the merger.

08:46 EDT Mnuchin 'incredibly hopeful' tax reform could be done this year - Treasury Secretary Steve Mnuchin is speaking on CNBC.

08:45 EDT AT&T says expects CapEx steady at approximately $22B annually - Says will continue to invest aggressively in 5G networks.

08:44 EDT Mnuchin says still considering tax reform going back to Jan. 1 of 2017 - Treasury Secretary Steve Mnuchin is speaking on CNBC.

08:43 EDT Evoke Pharma completes dosing for Gimoti exposure PK study - Evoke Pharma announced that it has completed subject dosing for a comparative exposure pharmacokinetic, or PK, study comparing Gimoti to the listed drug, Reglan Tablets. Gimoti is the company's lead drug candidate for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis. The company expects to announce data from the trial in Q4, followed by a 505(b)(2) New Drug Application, or NDA, submission by the end of 2017 or early 2018. The study was designed to demonstrate that a proposed dose of Gimoti has a similar systemic exposure to that of the listed drug, Reglan Tablets. The study, conducted at a single study site, is a single dose, 4-way crossover design that enrolled approximately 100 healthy volunteers who each received Reglan Tablets and three different doses of Gimoti in a random sequence.

08:42 EDT AT&T says goal is to offer 1GBPS speed on all networks

08:42 EDT Wells Fargo CEO Sloan says looking at acquisition opportunities - Says capital levels "strong." Plans to return more capital to shareholders, including Q3's dividend of 39c per share. Sees Q3 loans impacted by by continued run off of junior lien mortgages and declines in the auto portfolio as tighter credit underwriting standards have slowed originations; partially offset by a modest increase in credit card outstandings. Says 2H net interest income performance to depend on factors, including level and slope of yield curve. Expects efficiency ratio to improve in 2H. Says has eliminated a layer of management in retail bank. Says looking at acquisition opportunities. Comments made at by CEO Tim Sloan at the Barclays Global Financial Services Conference.

08:35 EDT AT&T says working on low priced bundles for post-Time Warner close

08:33 EDT AT&T says experiencing record low churn in mobility business - Comments from Goldman Sachs Communacopia Conference.

08:31 EDT Saratoga Investment completes recapitalization of Easy Ice - Saratoga Investment announced it has completed the recapitalization of Easy Ice, one of the largest providers of ice machine service contracts to small businesses. During the quarter ended August 31 Saratoga completed a subsequent recapitalization, resulting in repayment of $10.2M and conversion of the remaining $16.5M of Saratoga's investment into a second lien position. Concurrently, Easy Ice established a new senior credit facility with Madison Capital, reducing its total cost of capital and providing additional growth capital while completing the significant acquisition of a regional competitor in the Chicago market.

08:27 EDT Intercept drops after Ocaliva liver injury warning letter sent to care providers - Shares of Intercept Pharmaceuticals (ICPT) are falling in pre-market trading after the company sent a letter to health care providers to highlight important prescriber information for Ocaliva, including the fact that liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis patients with moderate or severe hepatic impairment when Ocaliva was dosed more frequently than recommended. The letter, dated September 8, states that health care providers "should exercise a low threshold for drug discontinuation or interruption, based on laboratory, imaging and/or clinical evidence of toxicities." In pre-market trading, Intercept shares are down $18.58, or 16%, to $94.90. Reference Link

08:22 EDT Biomerica Inc commences clinical studies for H. pylori test - Biomerica announced that the company has commenced clinical studies to evaluate the performance of its new and proprietary Helicobacter pylori, or H. pylori, test. The clinical studies are being conducted at the University of Southern California, Vanderbilt University, and a European University. The patient clinical studies are expected to take 6 to 12 months to complete. The company will then need to complete the analytical studies and prepare for submission to the FDA and plans to utilize a 510(k) pathway clearance of the test. Biomerica's test is designed to increase the sensitivity and specificity of H. pylori testing and monitoring of treatment.

08:16 EDT Argos Therapeutics reports on interim analysis of Phase 3 ADAPT Trial - Argos Therapeutics reported on an update on the interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, or mRCC, that was presented on September 11 by Robert Figlin, MD, Professor and Chairman, Division of Hematology and Oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid, Spain. A total of 462 patients with previously untreated advanced or metastatic renal cell carcinoma were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib vs. sunitinib monotherapy after undergoing cytoreductive nephrectomy. As previously reported, as of February 3, 2017, the cut-off date for the most recent interim analysis which was conducted in February 2017, 42.7% of the 307 patients in the combination arm demonstrated an objective response by RECIST criteria, a secondary endpoint in the trial, as compared with 39.4% of the 155 patients in the control arm. Additional data from the trial reported for the first time at the ESMO Conference included data related to the duration of tumor response. Patients in the combination treatment arm who demonstrated an objective response had a median duration of response of 8.4 months compared to 6.3 months for patients in the control arm. Additionally, 16% of those patients with an objective response in the combination treatment arm had durable responses lasting at least 30 months compared to 7% of those who had an objective response in the control arm. Also of note, as of the date of the interim analysis, all of the patients in the combination arm who had achieved a duration of response of at least 30 months had maintained those responses through 36 months. In addition, Dr. Figlin updated immune response data that had been previously reported by the company, presenting data on 117 patients analyzed for immune response. Samples were collected from patients in the combination arm enrolled at US sites who provided consent for immune monitoring. Of the 117 patients for whom this analysis was completed, 96 met the criterion for inclusion in the pre-defined subgroup of immune responders, suggesting that Rocapuldencel-T is having its intended effect of stimulating an immune response in the majority of patients. Immune responders are defined as patients who have an increase of more than two standard deviations from the patient-specific baseline in the number of memory T cells at one or more time points. Of note, median overall survival at the time of the February interim analysis had not yet been reached in the subgroup of immune responders. Additionally, consistent with the mechanism of action of Rocapuldencel-T, a statistically significant correlation was observed between the increase from baseline in the number of Rocapuldencel-T-induced memory T cells and overall survival in patients for whom immune response data has been analyzed and who received at least seven doses of Rocapuldencel-T.

08:11 EDT Vivint Solar announces strategic agreement with ChargePoint - Vivint Solar announced a strategic agreement with ChargePoin to offer ChargePoint Home charging solutions and custom installations directly to residential customers. Vivint Solar will work with ChargePoint and other strategic collaborators to provide Fully Integrated Solar, the industry's most comprehensive residential product suite featuring a solar energy system, EV charger, home battery and smart home technology for intelligent energy management.

08:09 EDT CB&I awarded $50M contract for storage project in Central Asia - CB&I announced it has been awarded a contract valued at approximately $50M for a storage project in Central Asia. CB&I's scope of work includes the engineering, fabrication and construction of nine flat bottom tanks.

08:09 EDT FireEye names Vasu Jakkal CMO - FireEye announced that Vasu Jakkal has joined the company as chief marketing officer. Jakkal reports to FireEye CEO Kevin Mandia. In her role as CMO, Jakkal will oversee global marketing initiatives aimed at driving revenue and solidifying FireEye's reputation as a cybersecurity innovator and leader. Jakkal has 18 years of technology industry experience, most recently as vice president of corporate marketing at Brocade, where she focused on driving preference and demand for networking solutions and led the mission to raise the company's global awareness.

08:08 EDT Lockheed Martin awarded $45M contract from U.S. Air Force - The U.S. Air Force awarded Lockheed Martin a $45.5M contract to provide Military Code Early Use capability to the Global Positioning System. Part of the Air Force's overall modernization plan for the GPS, M-Code is an advanced, new signal designed to improve anti-jamming and protection from spoofing, as well as to increase secure access, to military GPS signals for U.S. and allied armed forces. MCEU will provide command and control of M-Code capability to eight GPS IIR-M and 12 GPS IIF satellites currently on orbit, as well as future GPS III satellites, which the Air Force expects will begin launching in 2018. MCEU is envisioned as a way to accelerate M-Code's deployment in order to support testing and fielding of modernized user equipment in support of the warfighter.

08:08 EDT Goldman co-COO says growth plans don't assume improved operating environment - Says growth plans don't assume an improved operating environment. Says not satisfied with recent performance in FICC. Says has seen "pretty steady decline" in FICC wallet since 2009. Says some aspects of lending currently mispriced. Says bank's FICC unit more weighted to market-making than peers. Says client mix no excuse for underpformance, says "completely committed" to improving performance. Sees more room to offer cash products to asset managers. Says FICC revenue opportunity could be higher than $1B if markets improve. Sees $12B lending opportunity for Marcus. Comments made by President and co-COO Harvey Schwartz at the Barclays Global Financial Services Conference.

08:06 EDT Teva receives FDA priority review for first line use of Trisenox in APL - Teva Pharmaceutical Industries said that the U.S. Food and Drug Administration has accepted for review the company's supplemental New Drug Application for the use of TRISENOX injection in combination with all-trans retinoic acid for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression. Currently, TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression. The FDA has accepted the sNDA for priority review with regulatory action expected in the first quarter of 2018. FDA grants priority review to applications for drugs or biologics intended to treat serious conditions and address unmet medical needs. The sNDA filing includes data from published scientific literature and a review of Teva's global safety database for arsenic trioxide.

08:04 EDT Alexion sees $250M in adjusted pretax savings annually by 2019

08:03 EDT Glenview Capital Management responds to DowDuPont spin-off plans - Glenview Capital Management issued the following statement regarding the announcement by DowDuPont: "We applaud today's announcement and the strong process that led to these significant improvements in the intended composition and sequencing of the DowDuPont spinoffs. We thank the leadership of each company for utilizing an unbiased third party in McKinsey & Company and for listening to the broad-based feedback from owners. Delivering these enhancements to the spinoff process within days of the creation of DowDuPont is an important first step in establishing premier governance principles befitting the history of these two franchises. As a next step, we look forward to the board's study of capital structure and capital allocation policy. Since management will likely be fully engrossed in achieving operational synergies and internally reorganizing under the new tri-company structure, it is unlikely that the strong free cash flow of the combined entity would be used to support material acquisitions in the intermediate term. As we believe DowDuPont remains significantly undervalued relative to the sum of its parts, we recommend the board adopt a meaningful share repurchase program promptly to reduce the overall cost of capital and to drive long-term shareholder value."

08:02 EDT Alexion to relocate headquarters to Boston, MA by mid-2018 - The restructuring will achieve savings by focusing the development portfolio, simplifying business structures and processes across the Company's global operations, and consolidating manufacturing capabilities. This includes: Research & Development: Eliminating spend and headcount associated with previously announced de-prioritized pipeline programs as well as optimizing additional R&D spend. As previously disclosed, these de-prioritized programs include ALXN1101 and ALXN6000 as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. Manufacturing and Site Consolidation: The new facilities strategy will result in the closing of multiple Alexion sites, including the Alexion Rhode Island manufacturing facility and certain regional and country-based offices. Alexion has had a positive working relationship with the state of Rhode Island, however, the Company is aligning its manufacturing facilities with its ongoing multi-product network manufacturing strategy, which utilizes Alexion's manufacturing operations in the U.S. and Ireland, and manufacturing capacity through its manufacturing partners. Commercial: Aligning investments with its core, high growth markets, optimizing the global operating structure to leverage synergies across regions and countries, reducing operating redundancies and focusing on continuity of the Company's field teams. General & Administrative: In parallel with the Research & Development and Commercial organizational changes, the Company is right-sizing certain G&A functions, such as Human Resources, Finance and IT, including out-sourcing certain non-core Finance and IT roles to support the realigned business. Alexion will continue to invest in other G&A functions, such as Legal and Compliance, to support its global business. Implementing these changes is expected to deliver approximately $270 million in GAAP pre-tax savings annually, inclusive of $20 million of share-based compensation savings, and approximately $250 million in non-GAAP pre-tax savings annually by 2019. These changes will position Alexion to deliver on its financial ambitions, including growing GAAP operating margin to 37% and non-GAAP operating margin to 50% in 2019. As part of these initiatives, Alexion plans to relocate its headquarters to Boston, MA by mid-2018. The Company plans to have approximately 400 positions in Boston. As the Company reorganizes to deliver on its re-focused strategy, Boston will provide access to a larger biopharmaceutical talent pool and a variety of life-sciences partners to further support future growth initiatives. New Haven, CT will be the Company's Center of Excellence for its world-class complement research and process development teams. The Company expects to record cumulative pre-tax restructuring and related expenses ranging between approximately $340 million and $440 million. Included in these amounts are: (i) employee separation costs of approximately $80 million to $90 million; (ii) asset-related charges of approximately $170 million to $210 million primarily related to asset impairments and accelerated depreciation of facilities to be closed; (iii) costs associated with relocating employees of approximately $40 million to $60 million and (iv) contract termination and other costs of approximately $50 million to $80 million. Approximately 50% of the restructuring and related expenses will result in cash outlays. Pre-tax restructuring and related expenses of approximately $240 million to $300 million are expected to be recorded in 2017.

08:01 EDT Recurrent Energy and Peninsula Clean Energy announce 15-year PPA - Recurrent Energy and Peninsula Clean Energy announced a 15-year Power Purchase Agreement, or PPA, for 100 megawatts of new solar power. Recurrent Energy is a wholly-owned subsidiary of Canadian Solar (CSIQ), and PCE is the community choice energy agency serving San Mateo County. Electricity will be delivered to PCE from Recurrent Energy's Mustang Two solar photovoltaic project in Kings County, in central California. The project is expected to reach commercial operation in 2019. Following commercial operation, the project will begin delivering power to PCE pursuant to the terms of the PPA.

08:00 EDT Alexion announces restructuring to advance corporate strategy

07:56 EDT Progress Software CEO issues shareholder letter on discussions with Praesidium - Progress' CEO Yogesh Gupta published an update on the company's strategy and business in a letter to shareholders, which included: "On September 27, when we formally report our third quarter performance, we will discuss further our strategy to support and grow our developer base and to be the platform of choice for the future of business application development... In keeping with this approach, we wanted to provide an update regarding recent discussions with Praesidium Investment Management, one of the company's largest shareholders. Praesidium is a long-time shareholder and we value their perspectives and ideas. In a Schedule 13D filing on August 2, Praesidium reported that it had met with our Board of Directors to "consider ways to enhance shareholder value." Among Praesidium's ideas was the consideration of a potential acquisition of a particular, unrelated third party. We evaluated the idea but ultimately concluded that it was not in the best interests of Progress or its shareholders. Our Board appreciated the suggestion, as well as the other constructive ideas to drive shareholder value, and we look forward to engaging in further discussions with Praesidium about their ideas. Praesidium has also suggested, among other things, that our Board consider adding specific individuals to our Board of Directors. Progress is committed to having a Board of Directors that has the right skills and diversity of experience and provides strong, independent oversight of the Company. Above all else, our Board is guided by shareholders' best interests in every decision. The Nominating and Corporate Governance Committee of our Board will consider these and other individuals when evaluating future changes to the composition of our Board. We are very pleased with our progress to date and excited about our future prospects, as we focus on continuing to enhance our strong core businesses. Based on our solid financial performance and the company's healthy cash flow generation, we look forward to closing out the fiscal year and beginning 2018 with good momentum."

07:51 EDT Progress Software raises quarterly dividend 12% to 15c per share - Progress announced that its Board of Directors approved a 12% increase in the company's quarterly cash dividend from 12.5c to 14c per share of common stock. This increased dividend will be paid on December 15 to shareholders of record as of December 1. The Board of Directors is committed to its policy of regularly returning capital to our shareholders and this marks the first increase in the dividend since the company began paying dividends at the beginning of fiscal 2017. The Board of Directors also set a target dividend payout ratio of between 25-30% of the company's annual cash flow from operations, reflecting the continued strength of the company's cash flow generation.

07:44 EDT Progress Software trading halted, news pending

07:42 EDT Weingarten Realty reports 'no significant damage' after Hurricane Irma - Weingarten Realty reported that after its preliminary inspections of a vast majority of the properties it seems fortunate as it didn't receive substantial damage from Hurricane Irma. The company continues to evaluate and inspect its 31 Florida properties as conditions allow. "Our thoughts and best wishes go out to our associates, tenants and all affected by this devastating storm. Although our properties have suffered minimal damage, we know there are many that have suffered much and we will continue to support the communities in which we operate," said Drew Alexander, president and CEO.

07:35 EDT 3ST Research files suit against Albany Molecular alleging fraud - 3ST Research announced the filing of litigation against Albany Molecular Research (AMRI). The lawsuit was filed on July 31 in the United States District Court in New Jersey. Dr. John Thottathil, a noted medicinal chemist and the lead scientist at 3ST Research, invented and patented novel technology to address the epidemic of opioid abuse. Dr. Thottathil initiated and then supervised the laboratory work on his inventions that had been subcontracted to AMRI. Having become aware of the value of this research, the lawsuit alleges that AMRI fraudulently appropriated this research for its own benefit, added AMRI employees as co-inventors to patents on Dr. Thottathil's research, and sought to gain control of this intellectual property for its own benefit. Together, these actions by AMRI have markedly slowed research in this time-sensitive and critically important medical field, and have blocked Dr. Thottathil from further pursuing advances using his own technology. In June 2017, AMRI announced that it had accepted an acquisition offer from The Carlyle Group (CG) and the private equity firm, GTCR. The acquisition was formally completed on August 31.

07:33 EDT Good Times Restaurants expands debt facility to $12M - Good Times Restaurants (GTIM) announced that it has amended its credit agreement with Cadence Bank (CADE), which expands the facility from $9M to $12M.

07:31 EDT Centrus Energy signs $70M in new nuclear fuel sales contracts - Centrus Energy announced that it has signed several new sales contracts in the last three months to supply its utility customers with low-enriched uranium fuel. The total value of the contracts is an estimated $70M, with deliveries through 2025.

07:31 EDT BioPharmX announces preliminary data from study of BPX-01 - BioPharmX is announcing preliminary data from a feasibility study of BPX-01 to assess the safety and efficacy of topical minocycline gel at both the 1% and 2% doses for the treatment of rosacea. The preliminary data from the ongoing study suggest good tolerability and promising efficacy of BPX-01 in this indication and highlight the value of BioPharmX's dermatology delivery system. This ongoing 12-week, open-label feasibility study to assess the safety and efficacy of BPX-01 topical minocycline gel in rosacea patients enrolled 20 subjects with moderate-to-severe papulopustular rosacea, who applied BPX-01 once daily.

07:23 EDT Goldman Sachs sees $5B in revenue growth opportunities over next three years - Sees $5B in revenue growth opportunities over next three years. Sees $2.5B+ in pre-tax earnings opportunities over next three years, 150bps ROE expansion opportunities in the same period. Comments from slides that will be presented at the Barclays Global Financial Services Conference.

07:22 EDT KemPharm announces FDRR process completion, resubmission of Apadaz NDA - KemPharm announced completion of the Formal Dispute Resolution Request, or FDRR, process with the FDA for Apadaz. Following detailed discussions with the FDA, KemPharm has responded to the Complete Response Letter (CRL) received on June 13, 2016 by submitting an amended New Drug Application, or NDA, for Apadaz. The FDA has notified the company with the determination that the NDA application for Apadaz is complete and has assigned February 23, 2018 as the expected date by which an approval decision will be determined. Apadaz is KemPharm's investigational product candidate that is intended to provide short-term management of acute pain.

07:15 EDT Nextchip licensed CEVA-XM4 imaging and vision platform - CEVA announced that Nextchip has licensed the CEVA-XM4 imaging and vision platform for its APACHE4 vision-based pre-processor targeted at real-time ADAS vision systems. Nextchip have incorporated CEVA's programmable vision platform into the APACHE4 alongside its differentiated image processing accelerators to enable advanced and affordable ADAS applications. APACHE4 is a vision-based pre-processor SoC targeting next-generation ADAS systems.

07:10 EDT Engine Capital urges Team to form cost-cutting, CEO search committees - Engine Capital publicly disclosed that it has delivered a letter to the Team's Board of Directors, in which it stated in part: "As you know from our August 23, 2017 letter, Engine Capital LP, together with its affiliates, has become a significant shareholder of Team, Inc. Team represents a significant investment for Engine...While we were pleased to hear from you that the Board is working on a series of initiatives to increase shareholder value and has hired legal and financial advisors as part of that process, we were disappointed by your apparent unwillingness to meet with us at this point to further discuss our recommendations and engage in a constructive dialogue. Given the urgency of the situation at Team, we feel it is best to share our thoughts publicly at this time." In the letter, Engine urges Team to: Immediately form a cost-cutting committee and hire a nationally-recognized consulting firm reporting to the committee with a particular focus on cost reductions; Immediately form a search committee to find the next leader of Team; Improve corporate governance and immediately start a process to refresh the Board. "On behalf of Engine, we look forward to working constructively with the Board and intend to closely monitor the developments at the Company. We must, however, reserve our rights to take whatever actions in the future we believe may be required to protect the best interests of shareholders," the investor concludes.

07:08 EDT Uranium Energy completes 43-101 mineral estimate for Alto Parana project - Uranium Energy announced that Minerals Advisory Group of Tucson, Arizona has completed a National Instrument 43-101 mineral resource estimate for the Alto Parana Titanium Project located in eastern Paraguay, approximately 100 km north of Ciudad del Este. The Company exercised its option to acquire 100% of the Project from CIC Resources on July 10 as previously reported.

07:05 EDT Sanofi reports new post-hoc analysis of Soliqua studies - Sanofi announced the report of a new post-hoc analysis of late-stage clinical trials of Soliqua 100/33. This post-hoc analysis reviewed data from the Phase 3 trials, LixiLan-O and LixiLan-L, which compared the effectiveness of Soliqua 100/33 vs. insulin glargine 100 Units/mL on top of metformin if previously taken in more than 1,900 adults with type 2 diabetes. Primary results and safety information for both studies were previously reported. Blood glucose levels were evaluated at 8 and 12 weeks, and the Kaplan-Meier method was used to estimate time to control, defined as time to first achieve an HbA1c of less than 7 percent or fasting plasma glucose of less than or equal to 7.2 mmol/L. In certain adults with type 2 diabetes, Sanofi's Soliqua provided blood sugar control earlier and in more adults than those treated with insulin glargine 100 Units/mL alone, according to the analysis, the company stated.

07:05 EDT Neovasc provides Tiara clinical update - Neovasc provided an update on the study progress and clinical performance of the Tiara valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation, one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death. To date, 34 patients have been treated with the Tiara valve at ten different medical centers across the United States, Canada, Germany, Italy, Belgium, Switzerland and Israel. The technical success rate in these implantations is 31/34 or 91.1%. In these technically successful implantations, paravalvular leak levels were reported as mild, trace or absent in 100% of these cases. All cause, 30-day mortality in the 33 patients who have reached 30 days post implant with Tiara is 12.1% (4/33). The remaining patient treated within the last 30 days is recovering well. To date, the longest surviving patient has passed 3.5 years post implant.

07:03 EDT Ladenburg Thalmann says Benson Financial Group joins Securities America - Securities America, a wholly owned subsidiary of Ladenburg Thalmann Financial Services, said it is pleased to welcome Benson Financial Group of Hannibal, Missouri.

07:02 EDT Bemis sees workforce reduction of about 8%, or 500 positions - In a regulatory filing, Bemis said it has completed its analysis and approved additional actions that will result in the closure of a total of four manufacturing facilities. In addition, the company will reduce its administrative support cost structure to align with the current business environment. In connection with the multi-year initiative, the company has estimated a reduction of 8% percent of its global administrative workforce, or 500 positions. In addition, the company plans to consolidate certain administrative offices and take other actions to improve the cost efficiency of a variety of administrative and operational processes. The company is targeting an annual savings run rate of $65M by 2019, before taxes, from the 2017 Plan. During the second quarter of 2017, the company recorded $16.2M in employee costs and $4.2M in fixed asset related costs. Based on current estimates and actual charges to date, the company now expects to incur total pre-tax restructuring expenses of $65M-$75M and total pre-tax other plan-related costs of $20M-$30M, with an additional $15M-$20M capital investment related to executing the 2017 Plan. Restructuring expenses include $35M-$40M in employee termination costs, $19M-$21M in fixed asset related expenses and $11M-$14M in other restructuring project costs, including the movement and re-installation of equipment. Other plan-related costs include consulting fees and the cost of customer trials and graphics associated with business moved to other manufacturing facilities. Plant closings are expected to be completed by the end of 2019. Total restructuring cash payments for the 2017 Plan are estimated to be $50M, with an additional $20M-$30M in other plan-related cash payments. The company expects restructuring and other plan-related payments of approximately $10M in 2017, with an additional $40M in 2018 and the balance in 2019.

07:02 EDT Eli Lilly announces results from Jardiance trial - New analyses of the landmark EMPA-REG OUTCOME trial showed that Jardiance, or empagliflozin, tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study. A reduction in cardiovascular death was also seen when Jardiance was added to common first and second-line diabetes medications, such as metformin or sulfonylurea. These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly and Company at the 53rd Annual Meeting of the European Association for the Study of Diabetes, or EASD, in Lisbon, Portugal.

06:58 EDT SunTrust sees 2017 adjusted tangible efficiency ratio 61%-62% - Sees 2019 adjusted tangible efficiency ratio less than 60%. Comments from slides that will be presented at the Barclays Global Financial Services Conference.

06:50 EDT Sage Therapeutics drops 23% to $68.00 following Phase 3 failure

06:49 EDT Store Capital raises quarterly dividend to 31c from 29c per share - On an annualized basis, this dividend of $1.24 per common share represents an increase of 8c per share over the previous annualized dividend. The dividend will be paid on October 16 to Store Capital stockholders of record as of the close of business on September 29.

06:46 EDT Corindus enrolls first patient in Precision GRX Registry study - Corindus Vascular Robotics announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the Company's second generation CorPath GRX System. The PRECISION GRX Registry will include up to 25 sites and enroll up to 1,000 patients receiving robotic-assisted percutaneous coronary intervention, or PCI. The study will gather data to evaluate patient outcomes, potential economic benefits, procedural parameters and the expanding capabilities of robotics in PCI.

06:44 EDT Raytheon to design, develop and manufacture projector for BAE Systems - Raytheon (RTN) will design, develop and manufacture the projector for BAE Systems' (BAESY) Digital Light Engine head-up display on the F-22 Raptor. The digital HUD upgrade will integrate seamlessly into the F-22's existing HUD space and enhance the pilot's situational awareness in the cockpit.

06:43 EDT Goodyear Tire to create new facility in Luxembourg - The Goodyear Tire & Rubber Company announced plans to create a new facility in Luxembourg that utilizes an innovative production process to meet growing customer and consumer demand for premium tires. Named Mercury, the proprietary process features highly-automated, interconnected workstations, using additive manufacturing technologies to efficiently produce premium tires in small-batch quantities on-demand for replacement and original equipment customers

06:39 EDT Georgia Power to begin full-scale Hurricane Irma damage assessment Tuesday - As Hurricane Irma clears Georgia, Georgia Power will begin its first day of full-scale damage assessment Tuesday. The company has experienced widespread, extensive damage due to high winds, heavy rain and fallen trees as a result of the historic hurricane. Damage assessment marks the first phase of the restoration process once the storm has left impacted areas. Georgia Power must wait until conditions are safe for damage assessment teams to enter the field and begin the restoration process, followed by repair crews, which could take several days, if not weeks, depending on the amount of damage and safe access to the area. As weather conditions improve, restoration efforts will accelerate, but it could take an extended period of time for all customers to be restored due to the vast damage from Hurricane Irma.

06:36 EDT Yingli Green Energy updates on partnership with Picasolar - Yingli Green Energy Holding announced an update on the partnership with Picasolar and the progress being made to deploy an innovative Hydrogen Super Emitter, or HSE, into pilot production under the Department of Energy SunShot Program. Yingli Americas partnered with Picasolar in 2016 and the collaboration received a $2M SunShot award with the goal of moving the selective emitter technology to production for n-type solar cells. Within the first year of the partnership, absolute efficiency improvements exceeding 0.3% absolute have been demonstrated on production cells and key reliability testing has been performed at third-party laboratories. Current work is focused on further improvements in cell efficiency, demonstrating cell-to-cell process uniformity, and scaling up the manufacturing equipment.

06:35 EDT Philip Morris report outlines fundamental transformation to smoke-free products - Philip Morris International published its sustainability report, outlining the fundamental transformation of the company to shift its business to smoke-free products. PMI's efforts are squarely focused on replacing cigarettes with smoke-free products, offering the millions of men and women who continue to smoke a better alternative. This second United Nations Global Compact Communication on Progress includes expectations for investment, resource allocation and progress towards a smoke-free future. In 2017, PMI expects over 70% of its global R&D expenditure and over 30% of its global commercial expenditure to be allocated to smoke-free products. The company indicates, as an aspirational goal, that by 2025 at least 30% of its volume will come from smoke-free products, assuming constant PMI market share.

06:31 EDT AXT completes acquisition of manufacturing facility in Dingxing, China - AXT announced that it has completed the purchase of its new manufacturing facility in the city of Dingxing in the People's Republic of China. Dingxing, located in the province of Hebei and under the jurisdiction of the prefecture-level city of Baoding, is approximately a 90-minute drive south of the company's current Beijing location. The new site, which features ample space for expansion, currently has three existing buildings, which comprise approximately 140,000 sq. feet of manufacturing space, and 50,000 sq. feet designated for offices and dormitories. AXT has acquired a total of approximately 18.8 acres and expects to increase manufacturing capacity at the new location as needed to meet customer requirements.

06:23 EDT Sandoz proposed biosimilar rituximab accepted for review by the FDA - Sandoz, a Novartis Division, announced that the FDA has accepted its Biologics License Application, or BLA, under the 351(k) pathway for a proposed biosimilar to the reference medicine, Rituxan (rituximab). Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

06:20 EDT DowDuPont CEO says intended companies will have stronger competitive positioning - "Our DowDuPont board is fully aligned and confident that these targeted portfolio adjustments are the right actions to take and will benefit all stakeholders over the long term," said Andrew Liveris, executive chairman of DowDuPont. "They bear out the clear results of a significant comprehensive analysis the Dow and DuPont boards undertook over the past many months, which benefited from a fresh look provided by independent, third-party external advisors, in particular McKinsey & Company. We built on the wealth of knowledge gained as both companies advanced our integration work together. These adjustments are also fully supported by the Materials Science Advisory Committee, as they better align select businesses with the market verticals they serve, while maintaining integration and innovation strengths within strategic value chains. As a result, both our Materials Science and Specialty Products divisions will be well-positioned to better anticipate and meet customer needs through focused innovation and technology development that will deliver accelerated growth from a broader suite of best-in-class products." Ed Breen, CEO of DowDuPont said, "The changes we are making will enhance the competitive advantages and value creation potential of DowDuPont and ensure that the intended companies have the best possible foundation to drive long-term value for all stakeholders. The facts clearly supported the strategic logic of this portfolio configuration. Each of the intended companies will have even stronger competitive positioning, high value-added customer solutions, and a distinct and compelling investment thesis, while maximizing opportunities for strategic growth and synergies. With clear focus, each will serve attractive and growing markets, investing in innovation and delivering greater returns for shareholders."

06:16 EDT Nordic American Tankers' new CFO Bjorn Giaever to join the company on October 16 - The company announced that New CFO Bjorn Giaever will join the company on October 16. Giaever joins NAT/NAO from the well reputed firm of Fearnley Securities AS with main office in Oslo, Norway. This is an investment bank with special focus on the maritime sectors, where he served as a director and partner in the Corporate Finance division. Mr. Giaever has served as a corporate advisor in the John Fredriksen group in London, top rated Senior Shipping Analyst in DNB Markets and partner in Inge Steensland AS, specializing in gas related maritime matters.

06:08 EDT AC Immune completes recruitment for Phase 1b study of ACI-24 for adults with DS - AC Immune announced that it has completed recruitment in its Phase 1b study of the first, low-dose cohort of adults with Down syndrome, or DS, a condition affecting one in about 700 newborns. In addition to cognitive dysfunction beginning in childhood, individuals with DS are predisposed to develop Alzheimer's disease-like characteristics at a much younger age and at much higher probability than the general population. The Phase 1b study is evaluating the safety, tolerability and immunogenicity of AC Immune's anti-Abeta vaccine ACI-24 and targeting Abeta related decline in individuals with DS. The trial is being conducted in collaboration with the Down Syndrome Center for Research and Treatment at the University of California San Diego, or UCSD, CA; St. Joseph's Hospital and Medical Center and Barrow Neurological Clinics, Phoenix, AZ; and Massachusetts General Hospital, Boston, MA. AC Immune and the Alzheimer 's Disease Cooperative Study at UCSD coordinate the trial.

06:06 EDT VivoPower executes transfer of the Amaroo Solar PV Project to ReNu for $1.91M - VivoPower International announced the execution of the Sale and Purchase Agreement for the transfer of the Amaroo Solar PV Project to ReNu Energy of Australia, pursuant to which ReNu Energy has paid a deposit of approximately $800,000 out of a total purchase price of A$2.38M or approximately $1.91M, with completion subject to typical closing conditions. The Amaroo Solar PV Project is the largest solar PV rooftop project in the Australian Capital Territory, and has been successfully operating since 2015. VivoPower will provide asset management services for the project.

06:03 EDT Starbucks unveils new cold-pressed espresso - Starbucks announced the development of a new, patent-pending cold extraction process that produces a concentrated, smooth tasting shot of cold-pressed espresso. The cold-pressed espresso shot will serve as the foundation for a new suite of in-store menu options focused on cold espresso beverages and will debut at the company's premium, Starbucks Reserve Roastery in Seattle beginning today. Since opening in December 2014, the Seattle Roastery has served as a pipeline of innovation for Starbucks including the introduction of Nitro Cold Brew which is now available in more than 1,000 stores nationwide and 16 markets globally.

06:01 EDT Southern Co: 925,000 Georgia Power customers without power due to Hurricane Irma - Hurricane Irma continues to impact service to Georgia Power customers with severe weather expected to continue overnight. As the storm clears the state, the company has secured additional resources and is prepared to respond with nearly 5,500 personnel from the company, other Southern Company operating companies and assisting utilities identified and ready to restore power as quickly and safely as possible following the storm. All of Georgia Power's resources are being held and dedicated to storm restoration efforts in the state following Hurricane Irma.

05:55 EDT AquaVenture provides business update after Hurricane Irma - AquaVenture provided an update on its Caribbean operations following Hurricane Irma. "I am pleased with the way our company has weathered the impact of Hurricane Irma. Irma affected us at our plants in St. Maarten, the US Virgin Islands, the British Virgin Islands, Turks and Caicos, and the Bahamas, as well as our operations center in Tampa, Florida. All Seven Seas Water employees are safe and accounted for. Through a combination of sound facilities construction and comprehensive storm preparation, our plants are either operating or ready to resume operations once electric power is restored. We expect to have all of our plants, except for our facility in the BVI, operating within one week. In the BVI, we are working with the government to restore power to our plant, which once restored will resume operations," said Doug Brown, AquaVenture's Chairman and CEO. "We are still very early in the process of gathering information and plan on providing an update regarding any financial impact on our earnings call for the third quarter. In the meantime, our team is working closely with our partners on the islands, relief organizations and local communities to assist in any way we can, and look forward to providing clean water to these communities going forward as the islands begin to recover and rebuild."

05:50 EDT Travelers estimates catastrophe losses for Hurricane Harvey $375M-$750M pre-tax - Travelers announced that it estimates its catastrophe losses relating to Hurricane Harvey, including estimated recoveries from reinsurance, will be in the range of $375M-$750M pre-tax and $245M-$490M after-tax. Consistent with the capital management strategy it employs during periods of significant catastrophe activity, the company also announced that it has temporarily suspended common share repurchases while it assesses losses from Hurricanes Harvey and Irma. Prior to suspending share repurchases, the company had repurchased approximately 2.6M shares for approximately $328M in the current quarter. The company provided the foregoing information in advance of its planned participation at the Barclays Global Financial Services Conference on September 12.